JP7695228B2 - ヒト及びイヌctla-4に対するイヌ化抗体 - Google Patents

ヒト及びイヌctla-4に対するイヌ化抗体 Download PDF

Info

Publication number
JP7695228B2
JP7695228B2 JP2022502245A JP2022502245A JP7695228B2 JP 7695228 B2 JP7695228 B2 JP 7695228B2 JP 2022502245 A JP2022502245 A JP 2022502245A JP 2022502245 A JP2022502245 A JP 2022502245A JP 7695228 B2 JP7695228 B2 JP 7695228B2
Authority
JP
Japan
Prior art keywords
seq
canine
amino acid
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541767A (ja
Inventor
モージー,モハマド
チャン,ユアンチョン
ターピー,イアン
Original Assignee
インターベット インターナショナル ベー. フェー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー. フェー. filed Critical インターベット インターナショナル ベー. フェー.
Publication of JP2022541767A publication Critical patent/JP2022541767A/ja
Priority to JP2025025886A priority Critical patent/JP2025081549A/ja
Application granted granted Critical
Publication of JP7695228B2 publication Critical patent/JP7695228B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022502245A 2019-07-15 2020-07-15 ヒト及びイヌctla-4に対するイヌ化抗体 Active JP7695228B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025025886A JP2025081549A (ja) 2019-07-15 2025-02-20 ヒト及びイヌctla-4に対するイヌ化抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874287P 2019-07-15 2019-07-15
US62/874,287 2019-07-15
PCT/EP2020/069924 WO2021009188A1 (en) 2019-07-15 2020-07-15 Caninized antibodies to human and canine ctla-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025025886A Division JP2025081549A (ja) 2019-07-15 2025-02-20 ヒト及びイヌctla-4に対するイヌ化抗体

Publications (2)

Publication Number Publication Date
JP2022541767A JP2022541767A (ja) 2022-09-27
JP7695228B2 true JP7695228B2 (ja) 2025-06-18

Family

ID=71620455

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022502245A Active JP7695228B2 (ja) 2019-07-15 2020-07-15 ヒト及びイヌctla-4に対するイヌ化抗体
JP2025025886A Pending JP2025081549A (ja) 2019-07-15 2025-02-20 ヒト及びイヌctla-4に対するイヌ化抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025025886A Pending JP2025081549A (ja) 2019-07-15 2025-02-20 ヒト及びイヌctla-4に対するイヌ化抗体

Country Status (8)

Country Link
US (1) US12552864B2 (cg-RX-API-DMAC10.html)
EP (1) EP3999539A1 (cg-RX-API-DMAC10.html)
JP (2) JP7695228B2 (cg-RX-API-DMAC10.html)
CN (2) CN114174336B (cg-RX-API-DMAC10.html)
AU (1) AU2020312687B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000604A2 (cg-RX-API-DMAC10.html)
CA (1) CA3145347A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021009188A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体
KR20250137204A (ko) 2022-12-27 2025-09-17 인베티엑스 인코포레이티드 신생아 fc 수용체(fcrn)에 대한 결합이 변경된 폴리펩타이드 및 사용 방법
CN121002059A (zh) 2023-01-20 2025-11-21 因外泰克斯公司 用于伴侣动物的双特异性结合剂
CN117343185B (zh) * 2023-12-06 2024-03-01 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512809A (ja) 2011-03-09 2014-05-29 アンチトープ・リミテッド ヒト化抗ctla4抗体
JP2017500867A (ja) 2013-12-20 2017-01-12 インターベット インターナショナル ベー. フェー. ヒトpd−1に対するイヌ化マウス抗体
WO2017062615A2 (en) 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
JP2017534267A (ja) 2014-09-30 2017-11-24 インターベット インターナショナル ベー. フェー. イヌpd−l1と結合するpd−l1抗体
JP2019506146A (ja) 2015-12-18 2019-03-07 インターベット インターナショナル ベー. フェー. ヒトおよびイヌil−4rアルファに対するイヌ化ヒト抗体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) * 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6703360B2 (en) * 2000-04-07 2004-03-09 Heska Corporation Compositions and methods related to canine IgG and canine IL-13 receptors
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2469833C (en) * 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
KR100845354B1 (ko) 2004-03-26 2008-07-09 화이자 프로덕츠 인코포레이티드 항-ctla-4 항체의 용도
CN101688925B (zh) * 2007-01-15 2012-12-26 拉皮斯坎系统股份有限公司 检测器系统
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
BR112012022338A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais direcionados a cd20
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
HK1201281A1 (en) * 2011-10-13 2015-08-28 Nexvet Australia Pty Ltd Canine/feline cd20 binding epitope and compositions for binding thereto
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP3954710A3 (en) * 2015-04-02 2022-07-20 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
HUE065861T2 (hu) * 2016-08-26 2024-06-28 Sanofi Sa Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
JP2022500037A (ja) * 2018-09-14 2022-01-04 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のための抗il4受容体抗体
CN114174336B (zh) * 2019-07-15 2024-10-11 英特维特国际股份有限公司 针对人和犬ctla-4的犬源化抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014512809A (ja) 2011-03-09 2014-05-29 アンチトープ・リミテッド ヒト化抗ctla4抗体
JP2017500867A (ja) 2013-12-20 2017-01-12 インターベット インターナショナル ベー. フェー. ヒトpd−1に対するイヌ化マウス抗体
JP2017534267A (ja) 2014-09-30 2017-11-24 インターベット インターナショナル ベー. フェー. イヌpd−l1と結合するpd−l1抗体
WO2017062615A2 (en) 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
JP2019506146A (ja) 2015-12-18 2019-03-07 インターベット インターナショナル ベー. フェー. ヒトおよびイヌil−4rアルファに対するイヌ化ヒト抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PLoS ONE,2018年,Vol.13, No.7: e0201222,pp.1-14

Also Published As

Publication number Publication date
AU2020312687B2 (en) 2026-07-30
BR112022000604A2 (pt) 2022-03-03
US12552864B2 (en) 2026-02-17
WO2021009188A1 (en) 2021-01-21
CN114174336B (zh) 2024-10-11
US20220251209A1 (en) 2022-08-11
AU2020312687A1 (en) 2022-01-27
JP2022541767A (ja) 2022-09-27
JP2025081549A (ja) 2025-05-27
CN119307505A (zh) 2025-01-14
CN114174336A (zh) 2022-03-11
CA3145347A1 (en) 2021-01-21
EP3999539A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
US10927172B2 (en) Caninized murine antibodies to human PD-1
JP2025081549A (ja) ヒト及びイヌctla-4に対するイヌ化抗体
JP2019506146A (ja) ヒトおよびイヌil−4rアルファに対するイヌ化ヒト抗体
US20260125476A1 (en) Caninized antibodies against canine ctla-4
RU2822460C2 (ru) Канинизированные антитела против человеческого ctla-4
RU2818586C2 (ru) Антитела против собачьего ctla-4
HK40109850A (en) Antagonistic anti-canine pd-1 antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250527

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250606

R150 Certificate of patent or registration of utility model

Ref document number: 7695228

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150